Pharmamarketeer

AstraZeneca’s phase III DAPA─HF trial of Farxiga to treat heart failure meets primary endpoint

AstraZeneca announced positive results from the landmark phase III DAPA─HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically─significant and clinically─meaningful reduction

Medhc-fases-banner
Advertentie(s)